Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 32961119

Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2020 Nov
First author
Ascierto PA

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2020 Nov;21(11):1394-1395. doi: 10.1016/S1470-2045(20)30544-1.
    note
    Source null
    related pmid
    32961120
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2021 Oct;22(10):e428. doi: 10.1016/S1470-2045(21)00537-4.
    note
    Source null
    related pmid
    34592191
    relationship
    Erratum in

Authors and identifiers

  1. name
    Ascierto PA
    type
    Author
  2. name
    Del Vecchio M
    type
    Author
  3. name
    Mandalá M
    type
    Author
  4. name
    Gogas H
    type
    Author
  5. name
    Arance AM
    type
    Author
  6. name
    Dalle S
    type
    Author
  7. name
    Cowey CL
    type
    Author
  8. name
    Schenker M
    type
    Author
  9. name
    Grob JJ
    type
    Author
  10. name
    Chiarion-Sileni V
    type
    Author
  11. name
    Márquez-Rodas I
    type
    Author
  12. name
    Butler MO
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Ascierto PA
    type
    Author
  2. name
    Del Vecchio M
    type
    Author
  3. name
    Mandalá M
    type
    Author
  4. name
    Gogas H
    type
    Author
  5. name
    Arance AM
    type
    Author
  6. name
    Dalle S
    type
    Author
  7. name
    Cowey CL
    type
    Author
  8. name
    Schenker M
    type
    Author
  9. name
    Grob JJ
    type
    Author
  10. name
    Chiarion-Sileni V
    type
    Author
  11. name
    Márquez-Rodas I
    type
    Author
  12. name
    Butler MO
    type
    Author
bibliography ids
  1. nci-bib-3ac402169b7c5a7086a1e5f8
book metadata
content sha256
ab456ee2c342ab877dd47cb07be674d0ae7d58066a442423cf664b20538bdd64
document type
citation
dois
  1. 10.1016/S1470-2045(20)30494-0
electronic publication date
display
2020 Sep 19
precision
day
year
2020
evidence scope
bibliographic_metadata_only
id
pubmed:32961119
immutable id
pubmed:32961119@ab456ee2c342ab877dd47cb07be674d0ae7d58066a442423cf664b20538bdd64
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
11
name
The Lancet. Oncology
nlm unique id
100957246
pages
1465-1477
volume
21
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2020 Nov;21(11):1394-1395. doi: 10.1016/S1470-2045(20)30544-1.
    note
    Source null
    related pmid
    32961120
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2021 Oct;22(10):e428. doi: 10.1016/S1470-2045(21)00537-4.
    note
    Source null
    related pmid
    34592191
    relationship
    Erratum in
outcomes validated
false
pmid
32961119
provenance
batch id
9bca82d1bba2b27adc79
provider
NCBI PubMed ESummary
record sha256
f3a5bd4dd715d7b0ad298bd487c01d6dbcc85454c2e17e56767b407f92625ab3
response sha256
c8a4853c65a45038af15f5ade3970763bfa121cf5c68bafcc52c3a06860d0211
retrieved at
2026-09-09T23:47:56.131551+00:00
publication date
display
2020 Nov
precision
month
year
2020
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/32961119/
title
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.

Preserved source evidence · Not medical advice